research Identification of Blood MicroRNA Alterations in Patients With Severe Active Alopecia Areata
Certain blood miRNAs are linked to severe alopecia areata and could lead to new treatments.
Search
forProducts matching "severe alopecia"
Tracking 4 products like 183 PROPECIA 1MG/*28 TABL, 183 PROPECIA 1MG/*28 TABL, 183 PROPECIA 1MG/*28 TABL and 183 PROPECIA 1MG/*28 TABL from by companies like OnlinePharmacy-BG, Inhouse Pharmacy, oasisstad.net and oxfordon line pharmacy. View all 4 products »
Sort by
Research
60-90 / 1000+ results research Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata
Corticosteroid pulse therapy is more effective for severe alopecia areata than combination therapy.
research Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three Patients
Adalimumab was safe but mostly ineffective for severe alopecia areata.
research Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Nail Involvement in Patients with Moderate-to-Severe Alopecia Areata Treated with Oral Tofacitinib
Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Efficacy and Safety of Baricitinib in Adult Patients With Severe Alopecia Areata With or Without an Atopic Background From Two Randomized, Placebo-Controlled, Phase 3 Trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Alefacept for Severe Alopecia Areata: A Randomized, Double-Blind, Placebo-Controlled Study
research Baricitinib as the First Systemic Treatment for Severe Alopecia Areata
Baricitinib is effective as a treatment for severe hair loss.
research Platelet-Rich Plasma And Topical Minoxidil 5% In The Treatment Of Severe Alopecia Areata: Report Of Two Cases
Combining platelet-rich plasma and minoxidil can effectively regrow hair in severe alopecia areata cases.
research Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Among Scalp Non-Responder Patients with Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment with Baricitinib Resulted in Meaningful Scalp Responses for Patients with Severe Alopecia Areata
Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Distribution of SALT Scores by Therapeutic Response in Patients with Severe Alopecia After 52 Weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
research Early Real-World Experience With Baricitinib in the Treatment of Severe Alopecia Areata
Baricitinib shows promise in treating severe hair loss.
research Diagnosis and Differential Diagnosis of Tertiary Androgenetic Alopecia With Severe Alopecia Areata Based on High-Resolution MRI
High-resolution MRI can distinguish between tertiary androgenetic alopecia and severe alopecia areata by measuring scalp and tissue thickness and hair follicle depth.
research Efficacy and Safety of Baricitinib in Managing Severe Alopecia Areata: A 6-Month Real-World Experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Reply to: Tofacitinib for the Treatment of Severe Alopecia Areata and Variants
More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Retrospective Cohort Study of 90 Patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Zinc Deficiency Associated with Hypothyroidism: An Overlooked Cause of Severe Alopecia
Zinc supplements may be needed to treat hair loss in hypothyroidism.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series
Combining high-dose corticosteroids with methotrexate may be effective and safe for severe alopecia areata.
research Combined Oral Pulse and Topical Corticosteroid Therapy for Severe Alopecia Areata in Children: A Long-Term Follow-Up Study
The combined therapy was effective and safe for children with severe alopecia areata.
research Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing Its Impact on T Regulatory Cell and NK Cell Populations
The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.